Oct 30, 2019
This working paper describes a targeted landscape review conducted in order to assess evidence in the existing literature regarding the characterisation and measurement of the biomedical innovation ecosystem. For the purposes of this paper, we use the term biomedical innovation ecosystem to encompass a dynamic network of activity which connects and combines different aspects of the therapeutic supply chain, including R&D, the pharmaceutical industry supply chain, medical professionals, regulatory and legislative elements of the drug testing and approval process, and deployment and adoption of the innovation and research outcomes.
The aim of the work is to identify existing indicators for the biomedical innovation ecosystem, as well as exploring wider considerations necessary in the conceptualisation and evaluation of the ecosystem. The work was conducted to support FasterCures as part of their wider project to develop a scorecard to measure the performance of the biomedical innovation ecosystem. The work is likely to be of interest to research funders and evaluators, particular those looking to develop indicators, or those interested in evaluation at a system level.
Introduction and context
Measuring the performance of the biomedical innovation ecosystem
Overview of a range of indicators used in the evaluation and assessment of academic biomedical and health research